The drug SI-B001 represents a potential advance in the treatment of relapsed multiple myeloma. This innovative antibody specifically interacts with BCMA within myeloma malignancies, leading to BCMA-dependent cellular https://sib001antibody522624.pointblog.net/izalontamab-si-b001-a-promising-novel-antibody-therapy-96051965